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Abstract
Deliberate and natural outbreaks of infectious disease, the prevalence of antibiotic resistant strains, and the ease by which
antibiotic resistant bacteria can be intentionally engineered all underscore the necessity of effective vaccines and continued
development of novel antimicrobial/antiviral therapeutics. Isoprenes, a group of molecules fundamentally involved in a
variety of crucial biological functions, are derived from either the mevalonic acid (MVA) or methylerythritol phosphate (MEP)
pathway. While mammals utilize the MVA pathway, many bacteria utilize the MEP pathway, highlighting the latter as an
attractive target for antibiotic development. In this report we describe the cloning and characterization of Francisella
tularensis MEP cytidylyltransferase, a MEP pathway enzyme and potential target for antibiotic development. Size exclusion
chromatography indicates the protein exists as a dimer in solution. Enzyme assays produced an apparent K
MEP
M ~178mM,
K
CTP
M ~73mM, k
MEP
cat ~1s{1 , k
CTP
cat ~0:8s{1, and a k
MEP
cat

K
MEP
M ~3:4|10
5 M
{1 min{1 . The enzyme exhibits a strict
preference for Mg
+2 as a divalent cation and CTP as the nucleotide. Titanium dioxide chromatography-tandem mass
spectrometry identified Thr141 as a site of phosphorylation. T141D and T141E site-directed mutants are catalytically
inactive, suggesting a mechanism for post-translational control of metabolic flux through the F. tularensis MEP pathway.
Overall, our study suggests that MEP cytidylyltransferase is an excellent target for the development of novel antibiotics
against F. tularensis.
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Introduction
Biothreat agents are classified by the US Centers for Disease
Control and Prevention (CDC) based upon their morbidity/
mortality rates, ease of dissemination, emergency response
procedures, and projected social impact. Category A and B
biothreat agents are of greatest concern and include Bacillus
anthracis (the causative agent of anthrax), Yersinia pestis (plague),
Francisella tularensis (tularemia), Brucella species (brucellosis), Burk-
holderia mallei (glanders), and Burkholderia pseudomallei (melioidosis).
Our vulnerability to both deliberate and natural outbreaks of
infectious disease is illustrated by the 2009 H1N1 swine flu
pandemic, 2003 SARS outbreak, 2001 anthrax letter attacks, and
1984 Rajneeshee Salmonella attacks, highlighting the necessity of
effective vaccines and antimicrobial/antiviral therapeutics. The
prevalence of antibiotic resistant strains and the ease by which
antibiotic resistance can be deliberately engineered into bacteria
further underscores the need for continued development of novel
antibiotics against new bacterial targets.
Antibiotic development generally proceeds through five distin-
guishable phases, including target identification, target validation,
lead molecule identification, lead molecule optimization, and
preclinical and clinical trials [1]. Comparative genomic investiga-
tions, utilizing bioinformatics and complete genome sequences,
has greatly empowered the target identification phase of novel
antimicrobial drug development [2]. Genome sequences reveal
that Francisella, Brucella, Bacillus, Burkholderia, and Yersinia each
harbor methylerythritol phosphate (MEP) pathway genes involved
in isoprene biosynthesis. Isoprenoids are a large and structurally
diverse class of molecules essential to a variety of crucial biological
functions, including cell wall biosynthesis (dolichols), the regulation
of membrane fluidity (hopanoids and cholesterol), electron
transport (quinones), and signal transduction (prenylated proteins).
Despite their diversity, all isoprenoids are synthesized from two
building blocks, isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMAPP), which are produced by the mevalonic acid
(MVA) or MEP pathway (Fig. 1). Because the MVA pathway is
exclusively utilized by mammals, the bacterial MEP pathway
enzymes are promising targets for the development of novel
antibiotics (reviewed in [3–5]).
Target validation typically involves loss of function assays (e.g.
small molecule inhibition and/or genetic knockout) to determine
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20884the essentiality of the target, followed by protein characterization
to ascertain its amenability to high-throughput screening (HTS)
assays (HTS is often used in the lead identification phase, wherein
large molecular libraries are screened for inhibitors of the target
protein). Growth inhibition by fosmidomycin [6] (a specific
inhibitor of MEP synthase) and lethal genetic knockouts of MEP
synthase (FTN_1483) and MEP cytidylyltransferase (FTN_0623)
[7] illustrate the vulnerability of F. tularensis to MEP pathway
inhibition. We recently detailed the enzymatic characterization of
F. tularensis MEP synthase and demonstrated its amenability to
high-throughput inhibitor screens [6]. We describe here the
cloning and enzymatic characterization of F. tularensis MEP
cytidylyltransferase and report on its tractability to HTS assays.
We detail the apparent Michaelis-Menten kinetic constants, survey
the cation and nucleotide specificity of the enzyme, and assess its
quaternary structure in solution. Additionally, we use titanium
dioxide chromatography-tandem mass spectrometry to identify a
site of phosphorylation on the enzyme, and suggest that
phosphoinhibition may serve to regulate metabolic flux through
the MEP pathway. Overall, our results validate MEP cytidylyl-
transferase as a promising target for the development of novel
antibiotics against F. tularensis.
Materials and Methods
Bacterial strains and growth conditions
Francisella tularensis subsp. holarctica Strain LVS (FSC 155) was
obtained through the NIH Biodefense and Emerging Infections
Research Resources Repository, NIAID, NIH, and was cultured
at 37uC in tryptic soy broth supplemented with 0.1% cysteine.
Escherichia coli BL21 CodonPlus (DE3)-RIL cells (Stratagene, La
Jolla, CA) were used for recombinant protein expression whereas
E. coli TOP10 (Invitrogen, Carlsbad, CA) or XL1Blue (Stratagene)
cells were used for general cloning procedures. E. coli was grown at
Figure 1. Two pathways of isoprene biosynthesis. A) The MVA Pathway. Three molecules of acetyl-CoA (1) are condensed to form 3-hydroxy-3-
methylglutaryl CoA (HMG-CoA) (3), which is then reduced to MVA by HMG-CoA reductase (4) [20,21]. MVA is further processed to yield IPP (7) [22–24],
which is converted to DMAPP (8) by an isomerase [25]. B) The MEP Pathway. Pyruvate (9) is condensed with glyceraldehyde 3-phosphate (10) to yield
1-deoxy-D-xylulose 5-phosphate (DXP; (11)) [26], an intermediate with a role in E. coli vitamin B1 and B6 biosynthesis [27–30] as well as isoprene
biosynthesis. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase (also called MEP synthase) catalyzes the reduction and rearrangement of 11 to yield
MEP (12) [31], the first committed step in the E. coli MEP pathway. The next enzyme, MEP cytidylyltransferase (or IspD), converts MEP into 4-(cytidine
59-diphospho)-2-C-methyl-D-erythritol (CDP-ME; (13)). CDP-ME kinase then phosphorylates CDP-ME, which becomes cyclized (coupled with the loss
of CMP) by cMEPP synthase to yield 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (15) [14,32–35]. A reductive ring opening of 15 produces 1-
hydroxy-2-methyl-2-butenyl diphosphate (HMBPP; (16)) [36–40], which is reduced to both IPP and DMAP in a ,5:1 ratio [4,41–46].
doi:10.1371/journal.pone.0020884.g001
F. tularensis MEP Cytidylyltransferase
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e2088437uC in Luria-Bertani (LB) media with constant shaking
(250 rpm). Protein expression was performed in LB media
containing ampicillin (100 mg/ml) and chloramphenicol (50 mg/
ml). Solid media were prepared by addition of 1.5% (wt/vol) agar.
Genomic and Plasmid DNA isolation
Genomic DNA was isolated from F. tularensis subsp. holarctica
using a Wizard Genomic DNA Purification Kit (Promega,
Madison, WI), per the manufacturer’s instructions. A GenElute
Plasmid miniprep kit (Sigma-Aldrich, St. Louis, MO) was used to
isolate plasmid DNA from E. coli.
Construction of the F. tularensis MEP cytidylyltransferase
expression plasmid
The MEP cytidylyltransferase coding region (ispD, FTL_1525)
was identified in the F. tularensis subsp. holarctica LVS genome
(accession number NC_007880) via a BLAST search using the E.
coli K12 homologous sequence as the query. Polymerase chain
reaction (PCR) primer pairs, designed to flank ispD (FtIspD-f; 59-
CACCGTGTCAAATAAATACGTAATTATTC -39 and FtIsp-
D-r; 59- ACCTAACTGCC AATTAGCATATTC -39), were pur-
chased from Sigma-Genosys (The Woodlands, TX) and used
to amplify the gene from purified genomic DNA. The primer
FtIspD-f contains four additional 59 residues (CACC) to facilitate
the unidirectional insertion of the PCR product into plasmid
pET101/D-TOPO (Invitrogen). FtIspD-r is designed to eliminate
the stop codon in the PCR product to permit the expression of a
C-terminal His-tagged MEP cytidylyltransferase protein. PCR was
performed with Platinum Pfx polymerase (Invitrogen) and the
following parameters: 2 minutes at 94uC followed by 30 cycles of
30 sec at 94uC, 30 sec at 53uC, 1.5 min at 68uC, and a final
elongation of 10 min at 68uC. A Qiaquick PCR Purification Kit
(Qiagen, Valencia, CA) was used to purify the PCR product,
which was then cloned into pET101/D-TOPO to create the
plasmid pFtIspD. Restriction mapping and DNA sequencing were
used to confirm the fidelity of the PCR and the correct
construction of the plasmid. pFtIspD was transformed into
chemically competent E. coli BL21 CodonPlus (DE3)-RIL cells
to express the protein.
Expression and purification of F. tularensis MEP
cytidylyltransferase
Shake flask cultures (1 L) were used for protein expression
(37uC, 250 rpm). A 10 mL overnight culture of E. coli BL21
CodonPlus (DE3)-RIL containing pFtIspD was used to inoculate
the shake flask and upon the cell density reaching an OD600 of 1.1,
protein expression was induced by the addition of 0.5 mM
isopropyl b-D-thiogalactopyranoside (IPTG). After incubation for
an additional 18 hours, cells were harvested by centrifugation and
stored at 280uC. To purify the His-tagged protein, the cell pellet
was thawed then cells were lysed using Lysis Buffer A (100 mM
Tris pH 8, .032% lysozyme; 3 mL per mg cell pellet), followed by
Lysis Buffer B (0.1 M CaCl2, 0.1 M MgCl2, 0.1 M NaCl, .020%
DNase; 0.3 mL per mg cell pellet). Clarified cell lysate was
obtained by centrifugation (48,000 x g, 20 min) then passed
through a TALON immobilized metal affinity chromatography
column (Clontech Laboratories, Mountain View, CA). The
column was washed with 15 column volumes of 1X equilibration
buffer (50 mM HEPES pH 7.5, 300 mM NaCl), 10 column
volumes of 1X wash buffer (50 mM HEPES pH 7.5, 300 mM
NaCl, 10 mM imidazole) and the His-tagged protein was then
eluted with 4 column volumes of 1X elution buffer (150 mM
imidazole pH 7.0, 300 mM NaCl). Buffer was exchanged by
addition of 0.1 M Tris pH 7.5, 1 mM NaCl while concentrating
the protein by ultrafiltration. Protein concentration was deter-
mined using the Advanced Protein Assay Reagent (Cytoskeleton,
Denver, CO) with c-globulins (Sigma-Aldrich) as the standard.
The protein was visualized via Coomassie stained SDS-PAGE and
a Western blot with an anti-His antibody (Qiagen). The yield of
purified MEP cytidylyltransferase averaged 20–30 mg per 1 L LB
shake flask.
Mutagenesis
The Thr141 to Asp141 and Thr141 to Glu141 mutants of MEP
cytidylyltransferase were engineered by GenScript Corporation
(Piscataway, NJ) using the pFtIspD plasmid as the template for
mutagenesis. The sequence of both mutant constructs were
confirmed by nucleotide sequencing. The mutant genes (in
pET101/D-TOPO) were transformed into chemically competent
E. coli BL21 CodonPlus (DE3)-RIL cells to express the C-terminal
His-tagged protein. The T141D and T141E mutants were purified
as described for the wildtype His-tagged MEP cytidylyltransferase.
Size-Exclusion Chromatography
The molecular mass of MEP cytidylyltransferase and the
mutant derivatives were estimated by loading 1 mg of protein
onto a Sephacryl 200HR (Sigma Aldrich, St. Louis, MO) size-
exclusion chromatography column equilibrated with 0.1 M Tris
pH 7.5, 1 mM NaCl (flow rate of 2 mL/min) and calibrated with
a gel filtration standard kit purchased from Bio-Rad (Hercules,
CA). Blue dextran was used to determine the void volume of the
column.
Fluorescence spectroscopy
Fluorescence spectra of wildtype and mutant MEP cytidylyl-
transferase were measured using a Fluoromax-3 fluorometer
(Horiba Jobin Yvon) at an excitation wavelength of 290 nm using
cuvettes with an optical path length of 1 cm. The emission spectra
of protein samples with a concentration of 5 mMi n0 . 1MT r i s
pH 7.5, 1 mM NaCl were measured from 310 to 400 nm
(excitation and emission slit width=5 nm). The temperature was
maintained at 30uC. All fluorescence spectra were corrected for
background with pure buffer.
Enzyme Assays
MEP cytidylyltransferase activity was evaluated using a coupled-
enzyme colorimetric assay, derived from that originally described
by Bernal et al [8]. To determine the apparent KM for 2-C-methyl-
D-erythritol 4-phosphate (MEP), the assay (200 mL) was per-
formed using 2.5 mM IspD, 100 mM Tris pH 8.0, 1 mM MgCl2,
1 mM DTT, 0.2 mM CTP, 100 mU/mL inorganic pyrophos-
phatase, and varying concentrations of MEP (Echelon Biosciences,
Salt Lake City, UT). The assay mixture was incubated at 37uC
while 40 mL aliquots were removed at 30 sec intervals and
combined with 120 mL water and 40 mL of an acidic malachite
green solution (2.4 M sulfuric acid containing 1.5% ammonium
molybdate, 1.6% Tween 20, and 9.5% malachite green). After a
10 minute incubation, sodium citrate was added to 3.4%. After an
additional 30 min incubation the A660 was spectrophotometrically
determined. A pyrophosphate standard curve was used to
calculate the rate of the enzyme. To determine the apparent KM
for CTP, the assay was performed as described but with a fixed
concentration of MEP (400 mM) and a variable CTP concentra-
tion. To determine cation specificity, assays were performed with
0.2 mM MEP, 0.2 mM CTP, and 1 mM MgCl2, CaCl2, CoCl2,
CuCl2, MnCl2, or ZnCl2. Nonlinear regression fitting to the
F. tularensis MEP Cytidylyltransferase
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constants. High-throughput assays were performed using 96-well
plates with assay volumes adjusted to 50 mL. The Z-factor was
calculated as described by Zhang et al [9] with calcium as the
inhibitor control.
Mass spectrometry method for phosphopeptide
identification
To obtain MEP cytidylyltransferase for phosphopeptide anal-
ysis, protein expression and purification was essentially as
described above, with the exception of using 0.01 mM IPTG for
induction. Purified MEP cytidylyltransferase was reduced with
10 mM DTT), alkylated by iodoacetamide (50 mM), and then
digested by trypsin (Promega) in buffer containing ammonium
bicarbonate (50 mM, pH 9) and urea (2 M). The digestion
mixture was then desalted by a SepPak column (Waters, Milford,
MA). Phosphopeptides were enriched from the tryptic peptides by
a TiO2 column as previously described [6]. The purified
phosphopeptides were analyzed by reversed-phase liquid chroma-
tography nanospray tandem mass spectrometry (LC-MS/MS)
using an LTQ-Orbitrap mass spectrometer (ThermoFisher) using
previously described methods [10]. Tandem mass spectra were
searched using the program SEQUEST (Bioworks software,
Thermo) with full tryptic cleavage constraints, static cysteine
alkylation by iodoacetamide, and variable phosphorylation of Ser/
Thr/Tyr. Phosphopeptide identification was determined using
database match scoring criteria filters followed by manual
evaluation of the raw data, as described [10].
Molecular Modeling
The F. tularensis subsp. holarctica LVS MEP cytidylyltransferase
(protein accession number CAJ79964) was homology-modeled
using I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TAS-
SER/) [11]. Templates were selected by I-TASSER’s threading
alignment algorithm which considers predicted secondary structure
features in the sequence and identifies analogous and homologous
protein templates. The optimized model was evaluated with
ProQRes [12], which uses atom-atom contacts, residue-residue
contacts, solvent accessibility, and secondary structure information
to assign an accuracy score from 0 (unreliable) to 1 (reliable). Swiss-
PdbViewer 4.0 (http://spdbv.vital-it.ch/) was used to visualize and
annotate the model.
Results and Discussion
Cloning, expression, and purification of F. tularensis MEP
cytidylyltransferase
The 690 bp ispD gene (FTL_1525) from F. tularensis subsp.
holarctica LVS encodes a polypeptide of 229 amino acids with a
calculated molecular mass of 25.9 kDa. The subsp. holarctica amino
acid sequence shares 99.1, 98.3, and 99.6% identity with the MEP
Figure 2. Purification of recombinant F. tularensis MEP cytidy-
lyltransferase. A) Coomassie stained SDS-PAGE showing a molecular
weight marker (MW) and purified His-tagged MEP cytidylyltransferase.
His-tagged MEP cytidylyltransferase has a predicted molecular weight
of 29.5 kDa. B) Western blot hybridization analysis of purified MEP
synthase using an anti-His antibody results in an intense band of the
expected size.
doi:10.1371/journal.pone.0020884.g002
Figure 3. Substrate dependent activity of F. tularensis MEP
cytidylyltransferase. Michaelis-Menten plot of reaction velocity as a
function of A) MEP concentration and B) CTP concentration. The solid
line represents the nonlinear least-squares best fit of the data to the
Michaelis-Menten equation. Each assay was performed in duplicate. The
R
2 value for each plot is indicated. Kinetic parameters derived from the
plots are listed in Table 1.
doi:10.1371/journal.pone.0020884.g003
F. tularensis MEP Cytidylyltransferase
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subsp. novicida (FTN_0623), and subsp. mediasiatica (FTM_1371),
respectively. PCR was used to amplify subsp. holarctica ispD and the
resulting product was cloned into an expression plasmid designed
to express a C-terminal His-tagged protein in E. coli. The
recombinant protein was purified by immobilized metal affinity
chromatography and the protein was visualized by SDS-PAGE
and Western blotting using an anti-His antibody (Fig. 2). Size-
exclusion chromatography using a calibrated column indicates
that the F. tularensis MEP cytidylyltransferase exists in solution as a
dimer (Fig. S1), similar to the MEP cytidylyltransferase from
Mycobacterium tuberculosis [13] and E. coli [14,15].
Kinetic characterization of F. tularensis MEP
cytidylyltransferase
The kinetic activity of purified MEP cytidylyltransferase was
spectrophotometrically evaluated by monitoring the substrate
dependent enzyme catalyzed production of pyrophosphate
(Fig. 1B). Nonlinear regression fitting of enzyme velocity versus
substrate concentration was used to determine the apparent kinetic
constants (Fig. 3 and Table 1). The K
app
M for MEP was obtained
using assays performed with a saturating concentration of CTP
(200 mM), whereas the K
app
M for CTP was determined using assays
with saturating levels of MEP (400 mM). Overall, the K
app,CTP
M for
the F. tularensis MEP cytidylyltransferase is similar to the reported
values for the E. coli and M. tuberculosis orthologs, when assayed
accordingly (Table 1), while the K
app,MEP
M is considerably larger for
the F. tularensis enzyme. Additionally, the catalytic turnover kcat ðÞ
of the E. coli and F. tularensis enzymes are comparable, while each
are slightly depressed relative to the M. tuberculosis ortholog
(Table 1). Combined with differences in apparent K
MEP
M values,
the disparity between the turnover numbers results in considerably
different specificity constants k
MEP
cat

K
MEP
M

for the F. tularensis
and M. tuberculosis enzymes. The biological significance of this
remains unclear. Interestingly, cation specificity assays reveal a
strict preference of the F. tularensis MEP cytidylyltransferase for
MgCl2 (Fig. 4), unlike the E. coli and Mycobacterium orthologs which
also accommodate Mn
+2 or Co
+2 [13,14]. Additionally, the F.
tularensis MEP cytidylyltransferase displays a clear preference for
CTP over alternative nucleotides (Fig. 5).
Phosphorylation of F. tularensis MEP cytidylyltransferase
Multifarious control mechanisms converge to collectively
regulate the activity of HMG-CoA reductase, thereby controlling
metabolic flux through the MVA pathway (reviewed in [16]). In
contrast, engineered expression studies suggest that several
pathway enzymes share control of regulating flux through the
MEP pathway (reviewed in [17]). We recently described the
phosphorylation of F. tularensis MEP synthase, illustrating its
potential for metabolic flux control and highlighting a region of
the protein that may be amenable to rational drug design [6]. To
ascertain if the F. tularensis MEP cytidylyltransferase might also be
phosphoregulated, we expressed the recombinant enzyme in E. coli
(induced with 10 mM IPTG), purified the His-tagged protein,
subjected the protein to trypsinization, and isolated and identified
phosphopeptides via titanium dioxide chromatography-tandem
mass spectrometry. Phosphothreonine 141 (equivalent to threo-
nine 140 in the E. coli homolog) was identified (Fig. 6a). The
resolved crystal structure of E. coli MEP cytidylyltransferase in
complex with CDP-ME (Fig. 6b) shows Thr140 positioned in the
substrate binding site, with the sidechain hydroxyl and backbone
amide groups hydrogen bonded to the C3 and C1 hydroxyl
oxygen atoms of ME, respectively [15,18]. Threonine 141 in the F.
tularensis homolog presumably has a similar role.
In light of the above observations, we hypothesized that
phosphorylation of Thr141 would disrupt the enzyme-substrate
interaction, negatively affecting enzyme activity. To test this
hypothesis, two mutants of F. tularensis MEP cytidylyltransferase
were created, T141D and T141E, wherein Thr141 was changed
to an aspartate or glutamate, respectively, which serve to mimic a
phosphothreonine. Each mutant was expressed in E. coli and
purified to near homogeneity via a C-terminal His-tag. Relative to
the wildtype enzyme, little difference was observed in the intrinsic
fluorescence maximum (Em lmax) for either of the mutants
(Fig. 7a), indicating that the introduction of the Asp or Glu has
Table 1. MEP cytidylyltransferase Apparent Kinetic Parameters.
MEP cytidylyl-
transferase K
MEP
M (mM) K
CTP
M (mM) k
MEP
cat (s
-1) k
CTP
cat (s
-1)
k
MEP
cat

K
MEP
M
(M
-1min
-1) Refer.
F. tularensis 177.9 +/- 35.2 73.0 +/- 14.9 1.0 +/- 0.10 0.8 +/- 0.05 3.4610
5 +/- 6.7610
4 This study
a
E. coli 61 +/- 14 370 +/- 60 58 +/- 6 760 +/- 60 0.7 25.9 +/- 5.9 - 54.1 +/- 28.0 6.6610
5 7.86610
6 [8]
a [18]
b
M. tuberculosis 43 58.5 +/- 5.4 92 53.2 +/- 4.5 3.4 0.012 - 0.017 4.7610
6 1.23610
4 [13]
a [47]
c
aColorimetric assay using malachite green.
bRadiometric assay using
14C-MEP.
cRadiometric assay using c-
32P-CTP.
doi:10.1371/journal.pone.0020884.t001
Figure 4. The divalent cation specificity of F. tularensis MEP
cytidylyltransferase. Enzyme assays were performed with the
indicated divalent cations at a fixed MEP (200 mM) and CTP (200 mM)
concentration. Relative enzyme activity reveals the strict preference of
the enzyme for Mg
+2. Each assay was performed in duplicate.
doi:10.1371/journal.pone.0020884.g004
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exclusion chromatography indicates that both mutants exist as
dimers in solution, as was observed with the wildtype isoform (Fig.
S1). Enzyme assays using the purified proteins reveal that 75% of
wildtype activity is lost with the T141D mutation, whereas the
T141E mutant is completely inactive (Fig. 7b). Collectively, these
results suggest that phosphorylation of Thr141 in F. tularensis MEP
cytidylyltransferase inhibits the enzyme, possibly serving as a
control mechanism for regulating metabolic flux through the MEP
pathway (analogous to the phosphoregulation of HMG-CoA
reductase [19], a kinase/phosphatase cycle may control metabolic
flux by phosphoregulating the activity of MEP synthase and MEP
cytidylyltransferase). Additionally, these results highlight Thr141
for the rational design of small molecule inhibitors of MEP
cytidylyltransferase.
F. tularensis MEP cytidylyltransferase and drug discovery
Lead molecule identification by high-throughput inhibition
assays typically involves the screening of large molecular libraries
using multi-well plate assays, a process that is highly dependent on
the quality and robustness of the assay, often described in terms of
the Z-factor [9]. An excellent high-throughput assay has a Z-factor
score between 0.5 and 1.0. To determine the Z-factor for the F.
tularensis MEP cytidylyltransferase assay, we adjusted the assay
volume to accommodate a 96-well plate, fixed the substrate
concentration at the Km (178 mM), used a saturating concentration
of CTP (200 mM), and evaluated three separate lots of purified
MEP cytidylyltransferase in a series of assays performed over three
consecutive days. Calcium, an inhibitor of pyrophosphatase, was
used as a positive control for inhibition. The Z-factor with F.
tularensis MEP cytidylyltransferase was found to be 0.8, indicative
of an assay (and enzyme) well suited for use in a high-throughput
screen.
Conclusions
The target validation phase of novel antibiotic drug develop-
ment typically involves genetic knockout assays to assess lethality
as well as protein purification and characterization to evaluate
amenability to HTS and/or rational drug design. While
transposon mutagenesis demonstrated the essentiality of MEP
cytidylyltransferase to F. tularensis viability, the protein remained to
be characterized. We demonstrate here that purified recombinant
F. tularensis MEP cytidylyltransferase is kinetically active and highly
amenable to use in HTS. Additionally, our investigation is the first
to show that MEP cytidylyltransferase may be phosphoregulated
at Thr141, further implicating a phosphoregulatory mechanism of
controlling metabolic flux through the F. tularensis MEP pathway,
as well as highlighting the residue for the rational design of enzyme
inhibitors.
Figure 6. Structural features of the MEP cytidylyltransferase. A) Predicted structure of the F. tularensis MEP cytidylyltransferase, homology-
modeled using templates selected by I-TASSER’s threading alignment algorithm. A cartoon representation of the dimeric enzyme is shown, with
alpha helices colored red, beta sheets colored yellow, and coiled regions colored gray. ProQRes was used to evaluate the quality of the model (Fig.
S2), providing scores ranging from 0 (unreliable) to 1 (reliable). Regions of the model scoring ,0.5 are colored light blue. Residues comprising the
substrate binding site (colored dark blue with backbone and sidechain residues shown) were identified via primary sequence alignment and the
resolved structure of E. coli MEP cytidylyltransferase [15]. Threonine141 (colored green with backbone and sidechain residues shown) is equivalent to
E. coli Thr140. B) Active site of the E. coli MEP cytidylyltransferase co-crystallized with CDP-ME (PDB accession code 1INI). Thr140 (arrow) hydrogen
bonds to the C1 and C3 hydroxyl oxygen atoms of CDP-ME [15,18].
doi:10.1371/journal.pone.0020884.g006
Figure 5. The nucleotide specificity of F. tularensis MEP
cytidylyltransferase. Enzyme assays were performed with the
identified nucleotide at either 200 mM or 400 mM, as indicated. The
assays contained a fixed MEP (200 mM) concentration. Each assay was
performed in duplicate. Relative enzyme activity reveals the preference
of the enzyme for CTP.
doi:10.1371/journal.pone.0020884.g005
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Figure S1 Molecular weight determination by size-
exclusion chromatography. Protein standards (&) were used
to calibrate the column. Linear regression fitting (R
2 is indicated)
generated the standard curve, which was used to determine the
molecular weight of wildtype MEP cytidylyltransferase (IspD) and
the two mutants (T141D and T141E).
(TIF)
Figure S2 ProQRes evaluation of the F. tularensis MEP
cytidylyltransferase structural model generated by I-
TASSER. ProQRes uses atom-atom contacts, residue-residue
contacts, solvent accessibility, and secondary structure information
to score the model over a sliding window of 9 residues [12]. Scores
range from 0 (unreliable) to 1 (reliable).
(TIF)
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